Discloses the use of a therapeutically effective amount of Ac-TMP-2 (SEQ ID NO:2) or a biologically active fragment or variant of Ac-TMP-2 having at least 80% sequence identity to the amino acid sequence of SEQ ID NO:2 in the manufacture of a medicament administrable to a subject to reduce or alleviate inflammation, inflammatory bowel disease and asthma, wherein the sequence is as defined in the complete specification.
